Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin
(Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly
subjects (aged ≥ 65 years) with community-acquired pneumonia (CAP) who required initial
IV therapy. This study also included an assessment of the clinical and bacteriologic
effectiveness of both drugs.
Phase:
Phase 4
Details
Lead Sponsor:
Bayer
Treatments:
Levofloxacin Moxifloxacin Norgestimate, ethinyl estradiol drug combination Ofloxacin